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Biologie en Santé – Centre Hospitalier Universitaire, Angers, FranceAbstractAcinetobacter spp. have emerged as global opportunistic pathogen causing a wide range of infections. Emergence of carbapenem resistance in
these organisms is a matter of great concern. We report here the ﬁrst detection of Acinetobacter pittii clinical isolates in Lebanon carrying
either the blaNDM-1 or the blaOXA-72 gene.
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E-mail: makempf@chu-angers.frThe genus Acinetobacter comprises to date more than 50 species,
among which Acinetobacter baumannii is the most clinically
relevant, often associated with pneumonia, septicaemia, urinary
tract infections, wound infections and meningitis [1]. Treatment
of infections caused by this opportunistic bacterium is a chal-
lenge as a result of its strong ability to develop resistance to a
wide range of antimicrobial agents, especially carbapenems. This
resistance trait is mainly related to production of acquired
carbapenem-hydrolyzing class D β-lactamases and metallo-
β-lactamases [2]. In the last decades, the role of non-baumannii
Acinetobacter in human infections has been increasingly recog-
nized as a result of advances in molecular biology [3]. There are
several reports of multidrug-resistant strains of Acinetobacter
pittii and Acinetobacter nosocomialis in healthcare facilities around
the world [4].
This study was initiated by the isolation of two imipenem-
resistant A. pittii strains recovered in two hospitals in Tripoli,
North Lebanon, in 2015. The ﬁrst one, designated CMUL332,© 2016 The Author(s). Published by El
This is an open access artiwas isolated from the urine of a 4-month-old child who was
admitted to the intensive care unit for fever and nephritic
syndrome. The second one, CMUL334, was isolated from the
urine of a 15-year-old girl patient hospitalized with febrile
gastroenteritis. Bacterial identiﬁcation was performed by
matrix-assisted desorption ionization–time of ﬂight mass
spectrometry and partial rpoB gene sequencing [5]. Antimi-
crobial susceptibility was determined by the disk diffusion
method according to the recommendations of the European
Committee on Antimicrobial Susceptibility Testing (http://
www.eucast.org). Both isolates were resistant to ticarcillin,
ticarcillin/clavulanate and ceftazidime and were of intermediate
susceptibility to piperacillin/tazobactam. In contrast, they
remained susceptible to aminosides, tigecycline, rifampin, cip-
roﬂoxacin and colistin, except strain CMUL332, which was
resistant to tobramycin and netilmicin. The Etest method
conﬁrmed the carbapenem-resistant phenotype because the
minimum inhibitory concentration for meropenem was
>32 mg/L and for imipenem either >32 mg/L (CMUL332) or
16 mg/L (CMUL334). Screening of blaOXA-23-like, blaOXA-24-like,
blaOXA-58-like and blaNDM genes by real-time PCR revealed that
CMUL332 harboured the blaNDM gene, while CMUL334 carried
the blaOXA-24 like gene. Sequencing of the entire carbapanemaseNew Microbe and New Infect 2016; 12: 43–44
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variants, respectively.
OXA-72-producing A. pittii was ﬁrst described in Colombia
in 2012 from a catheter tip–positive culture of a patient who
had ischaemic hepatitis and multiorgan failure [6]. This enzyme
has subsequently been reported from carbapenem-resistant
clinical isolates of A. pittii in France [7]. On the other hand,
identiﬁcation of NDM-positive non-baumannii Acinetobacter is
now increasingly reported worldwide, concomitantly with
those of A. baumannii isolates. Indeed, recent studies have
demonstrated the emergence and the dissemination of NDM-
1-producing A. pittii in several countries, including China [4,8],
Turkey [9] and recently Brazil [10].
This study is the ﬁrst report of A. pittii producing OXA-72
and NDM-1 in Lebanon, which highlights the clinical relevance
of this bacterium, in accordance with a series of recent studies
[3]. Therefore, surveillance is warranted, and early detection
of carbapenemase genes is recommended to avoid their major
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